<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371059</url>
  </required_header>
  <id_info>
    <org_study_id>2005-005087-93</org_study_id>
    <secondary_id>ISRCTN 24953404</secondary_id>
    <nct_id>NCT00371059</nct_id>
  </id_info>
  <brief_title>Memantine for Agitation in Dementia</brief_title>
  <acronym>MAGD</acronym>
  <official_title>Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Kent Hospitals University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Psychiatry, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>East Kent Hospitals University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the
      acute situation i.e under 12 weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Agitation is a cause of morbidity and mortality in Alzheimer's due to distress and use of
      medication with side effects. Memantine has beed shown to be associated with less agitation
      and a recent study by forrest pharmaceuticals failed to recruit. We will perform a 12 week
      rct in 164 patients to test this hypothesis in a locality with no competing studies and in a
      clinical setting where the drug is not often used. We will compare with placebo and also use
      a rescue protocol derived from international best practice.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohen-Mansfield</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory 6+12 weeks</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression 6+ 12 weeks</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Impairment Battery 6+12 weeks</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life 6+12 weeks</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Co-meds</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of agitation</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue protocol</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Dementia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Memantine 10mg BD</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 10 mgs BD</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Residential/Inpatients at recruitment to the study with a history of at least 2 weeks
             behavioural disturbance.

          2. Alzheimer's Disease only as per McKhann Criteria + Hachinski Score&lt;=4.

          3. Moderately severe to severe Alzheimer's Disease (baseline MMSE &lt;/=19).

          4. Clinically significant agitation that requires treatment.

          5. Severity of agitation defined by Cohen Mansfield agitation inventory (CMAI) &gt; /=45.

          6. Age &gt;/= 55.

        Exclusion Criteria:

          1. Memantine usage in the 4 weeks prior to the start of the study.

          2. On Cholinesterase inhibitor for less than 3 months and not on a stable dose.

          3. Anti-psychotic, anti-epileptic, antidepressant, benzodiazepine, lithium or hypnotic
             dosage alteration in the 2 weeks prior to the start of the study.

          4. Antiparkinsonian medication.

          5. Hypersensitivity to memantine or any of the excipients in the formulation.

          6. Severe renal impairment.

          7. Epilepsy, history of convulsions or seizure, or receiving any anti-epileptic
             treatment.

          8. Concomitant usage of N-methyl-D-aspartate (NMDA) antagonists such as amantadine,
             ketamine or dextromethorphan.

          9. Recent myocardial infarction, uncompensated congestive heart failure and uncontrolled
             hypertension.

         10. Severe, unstable or poorly controlled medical illness.

         11. Any disability that may interfere with the patient completing the study procedure.

         12. Active malignancy.

         13. Delirium, pain or any medical illness as a clear cause of agitation.

         14. Any important drug interactions: Prohibited during study and in the 14 days preceding
             enrollment/inclusion are: Analgesic dextromethorphan, Dopaminergics- amantadine,
             Warfarin due to theoretical INR prolongation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHRIS FOX, MBBSBscMSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CHRIS FOX, MBBSBscMsc</last_name>
    <phone>44-130-322-8836</phone>
    <email>DrChris.Fox@ekentmht.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ADRIAN TRELOAR, MB BS Bsc</last_name>
    <phone>44-132-262-5700</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oxleas Nhs Foundation Trust</name>
      <address>
        <city>Dartford</city>
        <state>Kent</state>
        <zip>DA2 7WG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kent and Medway NHS and Social Care Partnership Trust</name>
      <address>
        <city>Folkestone</city>
        <state>Kent</state>
        <zip>ct20 1jy</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MONICA CRUGEL, MRCPSYCH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2006</study_first_posted>
  <last_update_submitted>May 7, 2008</last_update_submitted>
  <last_update_submitted_qc>May 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>DR ART ATIONU</name_title>
    <organization>EAST KENT HOSPITALS TRUST</organization>
  </responsible_party>
  <keyword>Agitation</keyword>
  <keyword>Dementia</keyword>
  <keyword>Alzheimer's</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

